Background {#Sec1}
==========

Cancer-immunity cycle model was established in 2013 to describe a series of stepwise events regulating anti-tumor immune response \[[@CR1]\]. In this model, immune checkpoints act as inhibitory modulators and help cancer cell escape immune surveillance \[[@CR2], [@CR3]\]. As a vital immune checkpoint molecule, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is constitutively expressed by regulatory T cells (Tregs) but transiently expressed by conventional T cells post activation \[[@CR4]--[@CR6]\]. Apart from T cell receptor (TCR) recognizing antigen peptide-major histocompatibility complex, CD28 binding to CD80 or CD86 is an essential co-stimulatory signal for T cells activation. CTLA-4 is a competitive antagonist for CD28-CD80/86 binding which further impedes priming and activation of T cells \[[@CR7]\].

Similarly to CTLA-4/CD28 pathway, programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis is another important regulatory signal determining immune status \[[@CR8]\]. PD-1 is mainly expressed on activated T cell which could transduct extracellular signal (PD-L1) \[[@CR9]\]. Intracellular domains of PD-1 subsequently inhibit Ras-Raf-MEK-ERK and PI3K-AKT pathways by which extracellular PD-L1 undermines cytotoxicity activity of T cell \[[@CR10], [@CR11]\].

In theory, anti-PD-1 (α-PD-1) plus anti-CTLA-4 (α-CTLA-4) treatment simultaneously block two inhibitory signaling pathways of anti-tumor immune response \[[@CR12]\]. However, in some clinical trials, no significant advantage was observed in therapeutic effect parameters such as objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) for patients undergoing α-PD-1 plus α-CTLA-4 treatment, especially in comparison with α-PD-1 monotherapy treated patients \[[@CR13]\]. Besides, combination therapy might increase the risk of treatment related adverse event, causing treatment discontinuation \[[@CR14]\]. Therefore, the combination therapy might not absolutely bring benefit to patients.

To comprehensively compare the efficacy and safety of combination therapy of α-PD-1 and α-CTLA-4 with monotherapy, chemotherapy, and targeted therapy, we reviewed the relevant clinical trials and conducted this meta-analysis. Moreover, given the crucial role of PD-L1 expression in immune checkpoint inhibitor treatment, we performed a subgroup analysis to evaluate efficacy difference among different treatments in the context of high or low PD-L1 expression \[[@CR2]\].

Methods {#Sec2}
=======

Study design and systematic review protocol {#Sec3}
-------------------------------------------

This meta-analysis was designed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR15]\].

Participants, interventions, comparators {#Sec4}
----------------------------------------

Randomized controlled trials included in the meta-analysis all consisted of one treatment arm (α-PD-1 plus α-CTLA-4) and one or two control arms such as α-PD-1 or α-CTLA-4 monotherapy, chemotherapy, and targeted therapy. ORR, PFS, and OS were primary parameters to evaluate efficacy of treatment. Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 was adopted to measure treatment outcome. The safety of treatments was estimated by probability of any grade and 3--4 grade adverse event. The assessment of adverse event was according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).

Search strategy {#Sec5}
---------------

We searched PubMed and Cochrane Library databases for eligible studies on June 23 2019 with search terms and Boolean operators as following: "(((Ipilimumab) OR Tremelimumab)) AND (((((Atezolizumab) OR Avelumab) OR Durvalumab) OR Nivolumab) OR Pembrolizumab)".

Data sources, studies selections and data extraction {#Sec6}
----------------------------------------------------

All studies included in the meta-analysis met the following criteria: (1) randomized controlled trial; (2) efficacy and/or safety of α-PD-1 plus α-CTLA-4 therapy was investigated; (3) patients in control arm received other treatments except for combination treatment mentioned above; (4) efficacy and safety data were available in the paper. Studies were excluded according to the standards as: (1) non-randomized controlled trial; (2) efficacy and safety data were not available in the paper; (3) patients in control arm underwent combination treatment as well, aiming to explore the influence of dose on treatment effect; (4) article contained updated data in the followed-up paper.

Two authors (Ming Yi and Shuang Qin) independently selected studies met the inclusion criteria. All screened studies were filtered by title and abstract firstly. Then, uncertain studies were assessed by full-text review. For all studies included in meta-analysis, we extracted data including study name, first author name, cancer type, treatment arm, control arms, number of patients assigned into every arm, efficacy data, and safety parameters. For few studies without available Hazard Ratio (HR) and 95% confidence interval (CI), HR value was estimated from Kaplan--Meier curve by Engauge-Digitizer software.

The Cochrane Collaboration's tool for assessing risk of bias was employed to assess each involved study \[[@CR16]\]. Selection bias, performance bias, detection bias, attrition bias, as well as reporting bias were evaluated.

Data analysis {#Sec7}
-------------

Comparison of efficacy between combination therapy and other treatments was conducted by RR of ORR, HR of PFS and OS. Safety of treatment was evaluated by RR of adverse event. Heterogeneity among treatment groups was assessed by Chi square-based Q statistic. If I^2^ \> 50% or *p *\< 0.05, random-effect model was adopted \[[@CR17]\]. Otherwise, fixed-effect model was employed. A funnel plot with 10 studies or less is often misinterpreted, so we did not assessed publication bias \[[@CR18]\]. All data were performed by Stata software (version 12.0).

Results {#Sec8}
=======

Flow diagram, study selection, and characteristics {#Sec9}
--------------------------------------------------

As the literature retrieving process shown in Fig. [1](#Fig1){ref-type="fig"}, we searched PubMed and Cochrane Library databases and obtained total 668 studies after filtration of replicated document and article type. By reviewing title, abstract, and full-text, we finally selected 8 studies for meta-analysis which included 1730 combination therapy treated patients, 855 nivolumab (α-PD-1) treated patients, 362 ipilimumab (α-CTLA-4) treated patients, 546 sunitinib (targeted therapy) treated patients, and 583 chemotherapy treated patients. All included patients comprised 85 sarcoma patients, 160 esophagogastric cancer patients, 1153 melanoma patients, 1096 renal-cell carcinoma patients, 20 glioblastoma patients, and 1562 non-small cell lung cancer patients. Characteristics of eligible studies were shown in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow diagram of literature retrieval process Table 1Characteristics of clinical trials included in the meta-analysisStudy (phase)First authorCancer typeTreatment arm\
(No. of patients)Control arm 1\
(No. of patients)Control arm 2\
(No. of patients)Refs.Alliance A091401Phase 2D'Angelo SPSarcomaNivolumab plusIpilimumab (42)Nivolumab (43)\[[@CR29]\]CheckMate 032Phase 1/2Janjigian YYEsophagogastric CancerNivolumab plusIpilimumab (101)Nivolumab (59)\[[@CR13]\]CheckMate 067Phase 3Hodi FSMelanomaNivolumab plusIpilimumab (314)Nivolumab (316)Ipilimumab (315)\[[@CR30]\]CheckMate 069Phase 2Hodi FSMelanomaNivolumab plusIpilimumab (95)Ipilimumab (47)\[[@CR31]\]CheckMate 214Phase 3Motzer RJRenal-Cell CarcinomaNivolumab plusIpilimumab (550)Sunitinib (546)\[[@CR32]\]CheckMate 227^a^Phase 3Hellmann MDNSCLCNivolumab plusIpilimumab (583)Nivolumab (396)Chemotherapy (583)\[[@CR33]\]NCT02374242^b^Phase 2Long GVMelanomaNivolumab plusIpilimumab (35)Nivolumab (31)\[[@CR34]\]Checkmate 143^c^Phase 1Omuro AGlioblastomaNivolumab plusIpilimumab (10)Nivolumab (10)\[[@CR35]\]*NSCLC* non-small-cell lung cancer^a^583, 396, and 583 patients were assigned to Nivolumab plus Ipilimumab group, Nivolumab group, and Chemotherapy group in CheckMate 227 totally. However, the difference comparison among three groups was just conducted in patients harboring at least 10 mutations per megabase^b^NCT02374242 contained three cohorts: Cohort A (Nivolumab plus Ipilimumab, n = 35), B (Nivolumab, n = 25), and C (Nivolumab, n = 6). Among three cohorts, Cohort A and B consisted of patients with the same diagnosis and treatment. 60 patients were randomly assigned to Cohort A and B while 6 patients were selected to Cohort C. Therefore, the following analysis was based on Cohort A and B^c^Checkmate 143 consisted of three cohorts: Cohort A (Nivolumab, n = 10), Cohort B (Nivolumab plus Ipilimumab, n = 10), and Cohort C (Nivolumab plus Ipilimumab, n = 20). 20 glioblastoma patients were 1:1 randomly assigned to Cohort A and B while 20 patients were allocated to Cohort C. Thus, the following analysis was based on Cohort A and B

Synthesized findings {#Sec10}
--------------------

ORR was higher in combination therapy treated patients. Our meta-analysis showed that ORR of combination therapy treated patients was significantly higher than patients undergoing other therapies (pooled RR 1.54, 95% CI 1.30--1.83) (Fig. [2](#Fig2){ref-type="fig"}). Subgroup analysis showed that combined therapy had a great advantage over α-PD-1 treatment (pooled RR 1.31, 95% CI 1.16--1.48), α-CTLA-4 treatment (pooled RR 2.11, 95% CI 1.84--2.43), and chemotherapy or targeted therapy (pooled RR 1.41, 95% CI 1.26--1.58).Fig. 2Forest plot of risk ratio (RR). Relative objective response rate (ORR) of α-CTLA-4 plus α-PD-1 combination treatment compared with other treatments. CI: confidence interval

Outcome was better for patients undergoing combination therapy. Totally, compared with other treatments, both PFS (pooled HR 0.62, 95% CI 0.51--0.75) and OS (pooled HR 0.69, 95% CI 0.62--0.78) were improved in patients treated with combination therapy (Fig. [3](#Fig3){ref-type="fig"}). Results of subgroup analysis showed that combination treatment group had significantly improved PFS than α-PD-1 monotherapy (pooled HR 0.68, 95% CI 0.62--0.75), α-CTLA-4 monotherapy (pooled HR 0.41, 95% CI 0.35--0.49), and chemotherapy or targeted therapy (pooled HR 0.70, 95% CI 0.51--0.97) (Fig. [3](#Fig3){ref-type="fig"}a). However, results of subgroup analysis for OS showed a slightly different trend. Compared with nivolumab treatment, combination therapy had a moderate advantage in OS even without statistical significance (pooled HR 0.84, 95% CI 0.69--1.03) (Fig. [3](#Fig3){ref-type="fig"}b). In comparison with α-CTLA-4 alone, combination therapy significantly prolonged OS of patients (pooled HR 0.56, 95% CI 0.46--0.68). Limited by insufficient data, we could not conduct subgroup analysis of combination therapy vs. chemotherapy or targeted therapy (Fig. [3](#Fig3){ref-type="fig"}b). Nevertheless, available data of comparison of combination therapy vs. targeted therapy showed the advantage of combination therapy in OS (HR 0.71, 95% CI 0.57--0.88) (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 3Forest plot of hazard ratio (HR). Comparison of progression-free survival (PFS) (**a**) and overall survival (OS) (**b**) between α-CTLA-4 plus α-PD-1 combination treatment and other treatments. CI: confidence interval

Treatment related adverse event in combination therapy. We assessed the safety of combination therapy by rate of any grade adverse event and grade 3--4 adverse event. On the whole, there was no significant difference in total adverse event rate between combination therapy and other treatments (pooled RR 1.35, 95% CI 0.93--1.97) (Fig. [4](#Fig4){ref-type="fig"}). Subgroup analysis showed that neither α-PD-1 monotherapy (pooled RR 2.02, 95% CI 0.98--4.17) nor α-CTLA-4 monotherapy (pooled RR 1.78, 95% CI 0.81--3.90) had significant advantage in total adverse event over α-PD-1 plus α-CTLA-4 treatment. Intriguingly, patients undergoing combination therapy had lower risk of total adverse event than chemotherapy or targeted therapy treated patients (pooled RR 0.77, 95% CI 0.60--0.98). Then we evaluated high-grade adverse event caused by treatment. No significant difference existed between combination treatment and other treatments in general. However, it was notable that both α-PD-1 monotherapy and α-CTLA-4 monotherapy induced less grade 3--4 adverse events than combination therapy (pooled RR 1.94, 95% CI 1.24--3.04, vs. α-PD-1 monotherapy; pooled RR 1.70, 95% CI 1.34--2.16, vs. α-CTLA-4 monotherapy), while the risk of chemotherapy or targeted therapy related adverse event was significantly higher than combination therapy (pooled RR 0.81, 95% CI 0.65--0.99).Fig. 4Forest plot of risk ratio (RR). Relative total treatment-related adverse event rate (**a**) and grade 3--4 treatment-related adverse event rate (**b**) of α-CTLA-4 plus α-PD-1 combination treatment compared with other treatments. CI: confidence interval

Efficacy of combination therapy in different PD-L1 expression statuses. In view of that PD-L1 was adopted as a predominant biomarker to screen patients for α-PD-1 treatment, we compared the efficacy of combination therapy with other treatments. In comparisons of combination therapy vs. α-CTLA-4 monotherapy and vs. chemotherapy or targeted therapy, combined therapy showed significant advantages in ORR, PFS, and OS regardless of PD-L1 expression status (Figs. [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}). Notably, the advantages of combination therapy over α-PD-1 monotherapy were not consistent in different PD-L1 expression statuses. For patients with high PD-L1 expression (determined as ≥ 1% in the most studies), there was no significant difference between combination therapy and α-PD-1 monotherapy in ORR (pooled RR 1.26, 95% CI 1.00--1.57), PFS (pooled HR 0.91, 95% CI 0.69--1.21), OS (HR 0.98, 95% CI 0.71--1.36, data obtained from study CheckMate 067) (Figs. [5](#Fig5){ref-type="fig"}a, [6](#Fig6){ref-type="fig"}a, [7](#Fig7){ref-type="fig"}a). On the contrary, in the context of low PD-L1 expression (determined as \< 1% in the most studies), patients receiving combination therapy tended to have higher response rate than α-PD-1 monotherapy (pooled RR of ORR 1.35, 95% CI 1.11--1.65) (Fig. [5](#Fig5){ref-type="fig"}b). Moreover, combination therapy treated patients tended to have a better outcome even though without reaching statistical significance (pooled HR of PFS 0.52, 95% CI 0.22--1.21) than α-PD-1 monotherapy (Fig. [6](#Fig6){ref-type="fig"}b). Despite limited data, results of CheckMate 067 showed the advantage of combination therapy over α-PD-1 monotherapy in OS (HR 0.70, 95% CI 0.50--0.98) (Fig. [7](#Fig7){ref-type="fig"}b).Fig. 5Forest plot of risk ratio (RR). Relative objective response rate (ORR) of α-CTLA-4 plus α-PD-1 combination treatment compared with other treatments in the high PD-L1 expression status (**a**) and low PD-L1 expression status (**b**). CI: confidence interval Fig. 6Forest plot of hazard ratio (HR). Comparison of progression-free survival (PFS) between α-CTLA-4 plus α-PD-1 combination treatment and other treatments in the high PD-L1 expression status (**a**) and low PD-L1 expression status (**b**). CI: confidence interval Fig. 7Forest of hazard ratio (HR). Comparison of overall survival (OS) between α-CTLA-4 plus α-PD-1 combination treatment and other treatments in the high PD-L1 expression status (**a**) and low PD-L1 expression status (**b**). CI: confidence interval

Risk of bias {#Sec11}
------------

According to Cochrane Collaboration's tool for assessing risk of bias, we assessed the quality of all involved randomized controlled trials (Table [2](#Tab2){ref-type="table"}). As a whole, 8 studies included in the meta-analysis were high-quality random controlled trials with most information at low risk of bias. Besides, we conducted a sensitivity analysis by Stata software 12.0 with metainf command. The pooled values did not changed significantly in the condition that any one study was omitted (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Table 2Cochrane Collaboration's tool for assessing risk of biasStudyRandom sequence\
generationAllocation concealmentBlinding of participants and researchersBlinding of outcome assessmentIncomplete outcome dataSelective reportingAlliance A091401**√√××√√**Checkmate 032**√√×√√√**Checkmate 067**√√√√√√**Checkmate 069**√√√√√√**Checkmate 214**√√××√√**Checkmate 227**√√××√√**NCT02374242**√√××√√**Checkmate 143**√√××√√√**, low risk of bias; **× **, high risk of bias

Discussion {#Sec12}
==========

Immune checkpoint inhibitors relieve inhibitory tumor immune microenvironment and restore T cells activity from exhausted status. Reactivated T cells could effectively recognize tumor cell-derived neoantigen and subsequently kill tumor cell. However, in clinical practice, the application of immune checkpoint inhibitor is limited by unsatisfactory response rate. Patients undergoing α-CTLA-4 or α-PD-1 monotherapy are prone to primary or adaptive resistance to immune checkpoint inhibitor. However, based on our meta-analysis, primary resistance could be overcome by α-CTLA-4 plus α-PD-1 treatment. The primary reason is that simultaneously blocked two inhibitory signaling pathways have a synergistic effect for anti-tumor immunity \[[@CR19]\]. CTLA-4 mainly targets interaction between antigen presentation cells (APCs) and naïve T cells which interferes the expansion of T cells epitopes. Therefore, α-CTLA-4 broadens repertoire of TCR and enhances recognition of tumor associated antigen and neoantigen. Nevertheless, due to inhibitory tumor immune microenvironment, emergence of tumor specific T cells is a necessary but not sufficient condition for tumor elimination. Accompanied with accumulated tumor infiltrating lymphocytes, upregulated PD-L1 expression by inflammatory signals such as interferon-γ means deficient immune surveillance even though formation of "hot tumor". Based on that, we speculated that α-PD-1 could substantially reduce primary resistance. Moreover, we supposed that decreased probability of adaptive resistance contributed to the improved prognosis as well. Immunoediting during the cancer progression is an important reason for adaptive resistance \[[@CR20]\]. Broaden epitopes resulting from combination therapy could reduce the failure of recognition subclonal tumor cell-derived antigen, which provides durable and potent tumor-killing activity.

Despite all of this, the main concern of oncologists about combination therapy is the magnified risk of adverse event \[[@CR21]\]. Our meta-analysis showed that there was no significant difference between patients received combination therapy and monotherapy in total adverse event rate. Even though monotherapy had fewer high-grade adverse event rate than combination therapy, we believed that adverse event of combination therapy was acceptable especially compared with chemotherapy or targeted therapy.

Given that PD-L1 expression strongly relates with efficacy of α-PD-1 treatment. Therefore, we investigated efficacy of combination therapy in different PD-L1 expression statuses. Notably, in the context of high PD-L1 expression, the advantage of combination therapy in efficacy over α-PD-1 monotherapy is not significant. However, in the condition of low PD-L1 expression, outcome of combination therapy was obviously better than α-PD-1 monotherapy. Our analysis suggested that for patients with high PD-L1 expression, α-PD-1 monotherapy would be a better option for minimized adverse event and medical cost. On the other hand, for patients with low PD-L1 expression, α-CTLA-4 treatment could increase patients' sensitivity to α-PD-1 treatment. It is obvious that the combination therapy had better treatment effect than ipilimumab, chemotherapy, and targeted therapy in any PD-L1 expression condition.

In fact, other than α-CTLA-4, many interventions such as radiotherapy, oncolytic virus, and cancer vaccine have been adopted to enhance efficacy of α-PD-1 therapy \[[@CR22], [@CR23]\]. Due to interdependence between different anti-tumor immune stepwise events, enhanced neoantigen release, recognition, and priming/activation tumor-associated antigen or neoantigen specific T cells all indirectly promote downstream tumor-killing activity \[[@CR24]\]. The complexity of tumor immune microenvironment suggests it is hard to completely reverse inhibitory microenvironment by a single-target therapy \[[@CR25]\]. Therefore, combination therapy would be a promising strategy and deserves further attention.

The application of immune checkpoint inhibitors is changing the landscape of cancer therapeutics \[[@CR26], [@CR27]\]. In the meanwhile, from an economic point of view, it was reported the total healthcare cost of patients receiving nivolumab plus ipilimumab treatment was lower than patients undergoing nivolumab monotherapy or ipilimumab monotherapy \[[@CR28]\]. This cost advantage of combination therapy was attributed to the lower non-drug cost due to decreased hospitalization rates after initiation treatment \[[@CR28]\].

Some limitations still existed in our meta-analysis. Firstly, we resolved most heterogeneity by subgroup. However, we classified chemotherapy and sunitinib as one class named chemotherapy or targeted therapy, for distinguishing them from immunotherapy. Actually, this classification resulted in some heterogeneity existed in some subgroup analyses. Secondly, limited by amount of available studies, we did not analyzed efficacy of combination treatment in each specific cancer type, so our results should be carefully interpreted. Finally, our meta-analysis just included English literatures which might cause potential selection bias.

Conclusions {#Sec13}
===========

Combination therapy of α-CTLA-4 and α-PD-1 had significant advantages in efficacy over monotherapy, chemotherapy and targeted therapy without significantly increased adverse event. For high PD-L1 expression patients, combination therapy did not show obviously enhanced efficacy than α-PD-1. However, for low PD-L1 expression patients, simultaneous administration of α-CTLA-4 and α-PD-1 would be an optimized strategy to acquire better clinical benefits by overcoming primary drug resistance.

Supplementary information
=========================

 {#Sec14}

**Additional file 1: Figure S1.** Sensitivity analyses to evaluate stability of meta-analysis by omitting each study. **(A)** Sensitivity analysis for pooled risk ratio (RR) of objective response rate (ORR); **(B)** sensitivity analysis for pooled hazard ratio (HR) of progression-free survival (PFS); **(C)** sensitivity analysis for pooled HR of overall survival (OS); **(D)** sensitivity analysis of pooled OR of total treatment-related adverse event; **(E)** sensitivity analysis of pooled OR of grade 3--4 treatment-related adverse event.
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